<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方Med | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-31T16:28:54+08:00</updated>
  <subtitle>Best Evidence, Best Benefit</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>重磅发布！2020版新型抗肿瘤药物临床应用指导原则</title>
    <updated>2020-12-31T14:21:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/05_N2D6RH7qeKaGTED-Z_g</id>
    <link href="https://mp.weixin.qq.com/s/05_N2D6RH7qeKaGTED-Z_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>晚期NSCLC抗血管生成药物治疗中国专家共识：2020 vs 2019对比</title>
    <updated>2020-12-30T11:38:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/or9erhvq1T98BRUz6l-62g</id>
    <link href="https://mp.weixin.qq.com/s/or9erhvq1T98BRUz6l-62g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《柳叶刀》权威报告：中国前十大死因揭晓，中风第一，肺癌、肝癌前五</title>
    <updated>2020-12-28T11:50:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/ev99md4vUzc1S6QThD9P8Q</id>
    <link href="https://mp.weixin.qq.com/s/ev99md4vUzc1S6QThD9P8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重塑SCLC格局、改写NCCN指南！IMpower133试验设计背后的奥秘</title>
    <updated>2020-12-25T11:18:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/FzBtd1u_BeoX3Nq-jRNmZQ</id>
    <link href="https://mp.weixin.qq.com/s/FzBtd1u_BeoX3Nq-jRNmZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PARP抑制剂在晚期乳腺癌的OS获益：真实还是泡影？</title>
    <updated>2020-12-23T11:12:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-23:/s/7moM8waCF7sfWA1knDHluQ</id>
    <link href="https://mp.weixin.qq.com/s/7moM8waCF7sfWA1knDHluQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>SABCS重磅TOP5，留下哪些灵魂拷问？</title>
    <updated>2020-12-21T11:19:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/QaOcTt5p2ai_vD47_roLyw</id>
    <link href="https://mp.weixin.qq.com/s/QaOcTt5p2ai_vD47_roLyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚组分析，失败临床研究的一线生机？</title>
    <updated>2020-12-18T09:46:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/0ZbFIz44wkfh7x6SI81mig</id>
    <link href="https://mp.weixin.qq.com/s/0ZbFIz44wkfh7x6SI81mig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药魔方Med招聘：医学编辑</title>
    <updated>2020-12-16T11:09:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/8UT2_hnDJYpagfK3pfKrGg</id>
    <link href="https://mp.weixin.qq.com/s/8UT2_hnDJYpagfK3pfKrGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>五花八门的临床研究终点，傻傻分不清楚？</title>
    <updated>2020-12-15T12:29:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/jhRO218qQ5qn_FaAP83Vtw</id>
    <link href="https://mp.weixin.qq.com/s/jhRO218qQ5qn_FaAP83Vtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康69亿美元收购的DS-8201，临床试验设计有何奥秘？</title>
    <updated>2020-12-14T11:41:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/9qhy2MSrPRIZEcEWWxO19A</id>
    <link href="https://mp.weixin.qq.com/s/9qhy2MSrPRIZEcEWWxO19A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>